Adjuvant T-DXd is being investigated in the ongoing DESTINY-Breast05 trial, comparing T-DXd to T-DM1 in patients with residual invasive HER2-positive breast cancer following neoadjuvant therapy [24]. Here, ERBB2 is linked to breast carcinoma.